Nephrotoxicity of Oral Platinum Complexes
Author Information
Author(s): M.J. McKeagel, S.E. Morgan, F.E. Boxall, B.A. Murrer, G.C. Hard, K.R. Harrap
Primary Institution: Institute of Cancer Research
Hypothesis
The nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes is less than that of intravenous cisplatin and comparable to intravenous carboplatin.
Conclusion
Oral ammine/amine platinum (IV) dicarboxylates are not toxic to the kidneys in rodents at maximum tolerated doses.
Supporting Evidence
- Intravenous cisplatin caused significant kidney damage in both mice and rats.
- Oral ammine/amine platinum (IV) dicarboxylates did not cause proteinuria or glycosuria in mice.
- Rats treated with intravenous carboplatin showed normal renal function.
- Histological examination revealed no kidney damage from oral platinum complexes.
Takeaway
This study found that a new type of cancer drug taken by mouth doesn't hurt the kidneys like some older drugs do.
Methodology
The study compared the nephrotoxicity of intravenous cisplatin, intravenous carboplatin, and six oral ammine/amine platinum (IV) dicarboxylates in rodents using maximum tolerated doses.
Participant Demographics
Female Balb c-mice and female Wistar rats were used in all experiments.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website